Dendreon, the Seattle maker of an immune-stimulating therapy for prostate cancer, said today it will report the full results of a pivotal trial next week. The company already said the trial, called Impact, hit its main goal of helping men live longer, but the details will have to wait for a presentation at 2:20 pm Central time on April 28 at Room W375 in McCormick Place, the convention center in Chicago. Dendreon will hold a webcast to discuss the results further at 4:30 pm Central time that day.
Author: Luke Timmerman
Luke is an award-winning journalist specializing in life sciences. He has served as national biotechnology editor for Xconomy and national biotechnology reporter for Bloomberg News. Luke got started covering life sciences at The Seattle Times, where he was the lead reporter on an investigation of doctors who leaked confidential information about clinical trials to investors. The story won the Scripps Howard National Journalism Award and several other national prizes. Luke holds a bachelor’s degree in journalism from the University of Wisconsin-Madison, and during the 2005-2006 academic year, he was a Knight Science Journalism Fellow at MIT.
View all posts by Luke Timmerman
